

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Emerging Risk Factors Collaboration, (incl. Fletcher, A; Meade, T.W.), ; Wormser, D; Kaptoge, S; Di Angelantonio, E; Wood, AM; Pennells, L; Thompson, A; Sarwar, N; Kizer, JR; Lawlor, DA; Nordestgaard, BG; Ridker, P; Salomaa, V; Stevens, J; Woodward, M; Sattar, N; Collins, R; Thompson, SG; Whitlock, G; Danesh, J (2011) Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. *Lancet*, 377 (9771). pp. 1085-95. ISSN 0140-6736 DOI: [https://doi.org/10.1016/S0140-6736\(11\)60105-0](https://doi.org/10.1016/S0140-6736(11)60105-0)

Downloaded from: <http://researchonline.lshtm.ac.uk/115929/>

DOI: [10.1016/S0140-6736\(11\)60105-0](https://doi.org/10.1016/S0140-6736(11)60105-0)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

THE LANCET

Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: The Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. *Lancet* 2011; published online March 11. DOI:10.1016/S0140-6736(11)60105-0.

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

The Emerging Risk Factors Collaboration

Supplementary material

eTables

eTable 1 Descriptive summaries, grouped by study, of individuals with complete information on adiposity measures, age and sex	3
eTable 2 Description of methods used to assess adiposity measures in the contributing studies	5
eTable 3 Summary of data available and associations with adiposity measures	8
eTable 4 Hazard ratios for coronary heart disease and ischaemic stroke per 1-SD higher baseline BMI, waist circumference and waist-to-hip ratio levels with adjustment for baseline levels of potential biological mediators.....	10
eTable 5 Reclassification of 10-year predicted risk of cardiovascular disease after addition of BMI or waist-to-hip ratio or total and HDL-cholesterol measures to a non-lipid-based model.....	11

eFigures

eFigure 1 Flow diagram showing steps involved in study selection for the current analysis	12
eFigure 2 Mean adiposity measure levels in each study (part a), according to quantiles of adiposity measures (part b) and within 5-year age bands (part c)	13
eFigure 3 Cross-sectional associations of adiposity measures with lipid markers.....	14
eFigure 4 Cross-sectional associations of adiposity measures with systolic blood pressure, fasting glucose and some inflammatory markers.....	15
eFigure 5 Mean risk factors levels across thirds of waist circumference and waist-to-hip ratio by baseline BMI levels.....	16
eFigure 6 Mean waist circumference and waist-to-hip ratio levels by diabetes status at baseline, according to deciles of BMI levels	17
eFigure 7 Regression dilution ratios for adiposity measure levels plotted against time since baseline measurement by study	18
eFigure 8 Hazard ratios for coronary heart disease by clinically defined categories of baseline BMI and waist circumference levels	19
eFigure 9 Hazard ratios for coronary heart disease and ischaemic stroke across quintiles of baseline BMI, waist circumference and waist-to-hip ratio levels, among men and women	20
eFigure 10 Hazard ratios for coronary heart disease across thirds of waist circumference and waist-to-hip ratio by baseline levels of triglyceride	21
eFigure 11 Hazard ratios for coronary heart disease per 1-SD higher baseline BMI, waist circumference and waist-to-hip ratio levels, according to several individual and study level characteristics.....	22
eFigure 12 Study-specific hazard ratios for coronary heart disease per 1-SD higher baseline levels of adiposity measures, adjusted for age, sex, and smoking status in the BMI range ≥ 20 kg/m ²	23
eFigure 13 Funnel plots assessing potential bias due to small studies in the meta-analysis of adiposity measure and coronary heart disease risk.....	24
eFigure 14 Changes in C-index for cardiovascular disease risk prediction on omission of individual risk factors from a full model containing the Framingham risk score covariates plus BMI, waist circumference or waist-to-hip ratio in participants without diabetes at baseline	25
eFigure 15 Changes in C-index for cardiovascular disease risk prediction upon addition of BMI, waist circumference or waist-to-hip ratio on top of Framingham risk score covariates, according to different subgroups.....	26

eAppendix List of study acronyms and study references.....	27
---	----

eTable 1 Descriptive summaries, grouped by study, of individuals with complete information on adiposity measures, age and sex

Study design/ Study ^a	Total no with weight, height, waist & hip measured	Age (yrs) mean (sd)	Male (%)	BMI (kg/m ²) mean (sd)	Waist (cm) mean (sd)	Waist-to-hip ratio mean (sd)	Follow-up (yrs) median (5th & 95th percentiles)	Coronary heart disease (CHD) events	All CHD deaths	Non-fatal MI events	Ischaemic stroke events	Hemorrhagic stroke events	Unclassified stroke events	All cerebrovascular events	All cerebrovascular deaths	Cardiovascular disease events
Cohort studies																
ARIC ¹	14383	54 (6)	6213 (43)	28 (5)	97 (14)	0.92 (0.08)	14.0 (4.9 to 15.7)	865	198	667	455	56	16	564	24	1429
ATENA ^{11,c}	4741	50 (7)	0 (0)	27 (4)	85 (10)	0.82 (0.07)	6.7 (5.2 to 8.1)	18	1	17	1	2	0	4	0	22
ATTICA ²	1503	51 (11)	769 (51)	27 (4)	93 (14)	0.88 (0.11)	5.0 (5.0 to 5.0)	0	0	0	0	0	0	0	0	0
AUSDIAB ³	9204	53 (13)	4079 (44)	27 (5)	91 (14)	0.87 (0.09)	5.0 (4.8 to 8.5)	65	41	24	13	7	18	46	28	111
BRHS ⁴	3466	68 (5)	3466 (100)	27 (4)	97 (10)	0.95 (0.06)	5.0 (1.9 to 5.0)	160	92	68	3	1	104	112	26	272
BRUN ⁵	817	58 (11)	398 (49)	25 (4)	87 (11)	0.89 (0.07)	15.3 (3.9 to 15.5)	54	31	23	24	15	0	40	18	94
BWHHS ⁶	2779	68 (5)	0 (0)	27 (5)	85 (12)	0.81 (0.07)	7.3 (3.2 to 8.4)	89	13	76	0	1	89	90	1	179
CAPS ⁷	1062	62 (4)	1062 (100)	27 (4)	93 (10)	0.93 (0.06)	3.1 (1.8 to 3.3)	29	16	13	0	0	2	2	2	31
CHARL ⁸	428	71 (7)	179 (42)	27 (5)	95 (13)	0.94 (0.08)	11.8 (1.3 to 12.9)	56	28	28	2	4	31	39	14	95
CHS1 ^{9,b}	3881	72 (5)	1489 (38)	26 (5)	93 (13)	0.92 (0.09)	12.1 (1.9 to 12.9)	593	213	380	368	62	37	467	2	1060
CHS2 ^{9,b}	480	72 (5)	181 (38)	29 (5)	99 (15)	0.94 (0.07)	9.1 (1.7 to 9.5)	56	23	33	40	5	4	49	0	105
COPEN ¹⁰	8166	58 (15)	3502 (43)	26 (4)	87 (13)	0.87 (0.10)	13.2 (2.7 to 14.9)	509	41	468	368	73	121	591	44	1100
DRECE ¹²	497	57 (11)	222 (45)	28 (4)	95 (13)	0.92 (0.11)	1.5 (1.5 to 1.5)	0	0	0	0	0	0	0	0	0
EMOFRI ^{11,c}	360	55 (6)	176 (49)	26 (4)	91 (11)	0.90 (0.07)	6.8 (6.5 to 7.2)	2	0	2	2	1	0	3	1	5
EPESENCA ¹³	1001	77 (5)	333 (33)	27 (5)	93 (13)	0.88 (0.08)	4.0 (1.4 to 4.6)	45	17	28	30	5	15	50	4	95
FINRISK92 ¹⁴	5276	46 (10)	2446 (46)	26 (4)	88 (13)	0.86 (0.10)	11.8 (7.1 to 11.9)	150	31	119	84	36	0	124	7	274
FINRISK97 ¹⁴	6382	52 (11)	3167 (50)	27 (4)	90 (13)	0.87 (0.09)	6.8 (6.0 to 6.9)	109	34	75	75	19	0	95	5	204
FRAMOFF ¹⁵	2685	60 (9)	1183 (44)	28 (5)	99 (14)	0.94 (0.08)	5.2 (3.1 to 7.0)	51	4	47	24	1	0	25	0	76
GOH ¹⁶	634	70 (7)	305 (48)	28 (5)	99 (11)	1.03 (0.12)	3.9 (0.3 to 6.9)	0	0	0	0	0	0	0	0	0
GOTO13 ¹⁷	756	54 (0)	756 (100)	25 (3)	87 (9)	0.93 (0.05)	23.5 (5.0 to 30.5)	211	2	209	0	1	115	116	1	327
GOTO33 ¹⁸	729	51 (0)	729 (100)	26 (3)	95 (9)	0.93 (0.06)	12.8 (5.8 to 13.1)	27	13	14	0	0	8	8	0	35
GOTO43 ¹⁸	762	50 (0)	762 (100)	26 (3)	95 (9)	0.99 (0.06)	10.0 (7.9 to 10.7)	28	1	27	9	1	1	12	1	40
GOTOW ¹⁹	1401	47 (7)	0 (0)	24 (4)	74 (9)	0.74 (0.05)	32.2 (8.7 to 32.7)	147	54	93	0	0	174	174	34	321
HBS ²⁰	1268	60 (4)	1268 (100)	26 (3)	97 (9)	0.97 (0.06)	20.5 (6.0 to 20.5)	85	85	0	0	0	26	26	26	111
HISAYAMA ²¹	2515	59 (11)	1068 (42)	23 (3)	81 (9)	0.91 (0.07)	14.0 (3.2 to 14.0)	77	10	67	146	47	0	216	7	293
HOORN ²²	2226	61 (7)	979 (44)	27 (4)	91 (11)	0.89 (0.09)	8.8 (3.7 to 9.9)	73	13	60	3	4	46	53	11	126
IKNS ²³	1942	59 (10)	830 (43)	24 (3)	83 (9)	0.90 (0.07)	7.1 (4.1 to 14.6)	11	5	6	23	8	8	43	4	54
LASA ²⁴	1806	69 (8)	827 (46)	27 (4)	97 (11)	0.94 (0.08)	9.9 (1.8 to 10.4)	33	0	33	0	0	19	19	0	52
MATISS83 ^{11,c}	1317	61 (9)	614 (47)	29 (4)	94 (10)	0.91 (0.09)	8.7 (3.7 to 9.7)	20	3	17	13	6	17	36	1	56
MATISS87 ^{11,c}	1077	58 (9)	510 (47)	29 (4)	94 (11)	0.91 (0.09)	8.5 (5.0 to 9.5)	12	5	7	4	2	19	26	0	38
MATISS93 ^{11,c}	1206	49 (9)	579 (48)	28 (5)	91 (11)	0.91 (0.08)	8.3 (7.0 to 9.3)	14	3	11	1	2	3	7	0	21
MESA ²⁵	6768	62 (10)	3190 (47)	28 (5)	98 (14)	0.93 (0.08)	4.8 (2.5 to 5.2)	83	14	69	68	13	2	84	1	167

eTable 1 cont'd Descriptive summaries, grouped by study, of individuals with complete information on adiposity measures, age and sex

Study design/ Study ^a	Total no with weight, height, waist & hip measured	Age (yrs) mean (sd)	Male (%)	BMI (kg/m ²) mean (sd)	Waist (cm) mean (sd)	Waist-to-hip ratio mean (sd)	Follow-up (yrs) median (5th & 95th percentiles)	Coronary heart disease (CHD) events	All CHD deaths	Non-fatal MI events	Ischaemic stroke events	Hemorrhagic stroke events	Unclassified stroke events	All cerebrovascular events	All cerebrovascular deaths	Cardiovascular disease events
MOGERAUG2 ²⁶	3934	53 (12)	1935 (49)	27 (4)	90 (12)	0.87 (0.08)	7.9 (2.3 to 8.4)	102	41	61	1	1	3	7	7	109
MOGERAUG3 ²⁶	3368	55 (10)	1663 (49)	28 (4)	92 (12)	0.88 (0.09)	3.0 (1.8 to 3.6)	18	7	11	2	1	2	5	5	23
MONFRI89 ^{11,c}	1330	49 (8)	658 (49)	26 (4)	88 (12)	0.87 (0.09)	13.6 (6.6 to 13.7)	28	6	22	10	5	5	20	3	48
MONFRI94 ^{11,c}	1291	49 (8)	627 (49)	26 (4)	90 (12)	0.88 (0.09)	8.5 (7.2 to 8.8)	11	0	11	5	7	2	16	1	27
MORGEN ²⁷	17707	46 (9)	8046 (45)	26 (4)	88 (12)	0.86 (0.09)	10.8 (8.5 to 13.1)	77	77	0	3	10	4	24	24	101
MOSWEGOT ²⁸	4132	47 (11)	1966 (48)	25 (4)	85 (12)	0.86 (0.09)	12.9 (7.6 to 18.6)	141	39	102	65	17	15	116	8	257
MRCOLD ²⁹	9933	80 (4)	3747 (38)	26 (4)	90 (12)	0.88 (0.08)	8.7 (1.2 to 11.7)	1118	1118	0	52	59	504	821	821	1939
NHANESIII ³⁰	10450	53 (16)	4859 (46)	27 (6)	95 (14)	0.93 (0.09)	8.8 (4.2 to 11.7)	320	320	0	0	0	113	113	113	433
NSHS ³¹	1608	54 (15)	765 (48)	27 (6)	90 (15)	0.87 (0.10)	9.7 (3.7 to 10.0)	24	24	0	1	1	48	51	4	75
OSAKA ³²	717	49 (7)	602 (84)	23 (3)	84 (8)	0.90 (0.05)	7.7 (3.9 to 16.8)	4	2	2	3	1	2	6	0	10
PREVEND ³³	7368	50 (12)	3583 (49)	26 (4)	89 (13)	0.88 (0.09)	8.2 (6.7 to 8.9)	145	22	123	0	17	7	31	7	176
PRIME ³⁴	9563	55 (3)	9563 (100)	27 (3)	95 (10)	0.96 (0.06)	5.2 (5.0 to 7.3)	145	17	128	33	6	3	42	0	187
RANCHO ³⁵	1784	68 (11)	739 (41)	25 (4)	85 (12)	0.84 (0.09)	14.2 (2.0 to 18.1)	222	3	219	0	1	175	185	10	407
ROTT ³⁶	4607	68 (8)	1752 (38)	26 (4)	90 (11)	0.90 (0.09)	11.9 (3.2 to 14.1)	235	33	202	37	21	58	132	132	367
SHHEC ³⁷	3489	49 (11)	1625 (47)	26 (5)	86 (13)	0.85 (0.10)	10.0 (4.8 to 10.0)	119	44	75	26	9	24	70	5	189
SHS ³⁸	4135	56 (8)	1615 (39)	31 (6)	105 (15)	0.95 (0.06)	12.4 (2.1 to 14.3)	449	147	302	8	10	190	214	44	663
TARFS ³⁹	2559	49 (12)	1270 (50)	28 (5)	93 (12)	0.89 (0.09)	9.0 (2.0 to 10.0)	102	68	34	1	0	27	28	22	130
TOYAMA ⁴⁰	4523	46 (7)	2907 (64)	23 (3)	78 (9)	0.85 (0.07)	12.7 (7.8 to 12.8)	34	1	33	24	17	0	51	0	85
TROMSØ ⁴¹	1573	60 (10)	811 (52)	26 (4)	91 (11)	0.87 (0.08)	11.1 (2.6 to 11.3)	146	18	128	78	15	3	102	1	248
ULSAM ⁴²	962	71 (1)	962 (100)	26 (3)	94 (9)	0.94 (0.05)	12.2 (2.3 to 14.9)	137	43	94	83	15	7	111	4	248
WHITEII ⁴³	7862	49 (6)	5414 (69)	25 (4)	85 (11)	0.87 (0.09)	7.6 (3.8 to 8.2)	167	22	145	1	0	3	6	6	173
WHS ⁴⁴	24138	60 (7)	0 (0)	27 (5)	89 (14)	0.83 (0.08)	4.7 (3.0 to 5.6)	115	4	111	117	11	0	135	2	250
SUBTOTAL (54 studies)	218551	58 (9)	96391 (44)	27 (4.56)	91 (12.6)	0.90 (0.08)	7.9 (2.9 to 14.7)	7531	3047	4484	2306	596	2070	5407	1481	12938
Nested case-control studies																
EPICNOR ⁴⁵	1417	66 (8)	960 (68)	27 (4)	93 (11)	0.90 (0.08)	7.1 (2.2 to 9.3)	479	224	255	-	-	-	-	-	-
HPFS ⁴⁶	394	66 (8)	394 (100)	26 (4)	99 (10)	0.96 (0.06)	4.0 (0.8 to 4.0)	129	21	108	-	-	-	-	-	-
NHS ⁴⁷	372	58 (6)	0 (0)	25 (4)	81 (11)	0.79 (0.07)	12.0 (5.2 to 12.0)	151	16	135	-	-	-	-	-	-
WHIHBAPS ⁴⁸	1200	68 (6)	0 (0)	27 (6)	86 (13)	0.82 (0.09)	6.8 (1.2 to 9.3)	-	-	-	600	-	-	-	-	-
SUBTOTAL (4 studies)	3383	64 (7)	1354 (40)	26 (4.46)	90 (11.8)	0.87 (0.08)	6.9 (1.5 to 12.0)	759	261	498	600	-	-	-	-	-
TOTAL (58 studies)	221934	58 (9)	97745 (44)	27 (4.56)	91 (12.6)	0.90 (0.083)	7.9 (2.9 to 14.7)	8290	3308	4982	2906	596	2070	5407	1481	12938

^aeAppendix lists study acronyms and study references. ^bCHS included an original cohort (here termed CHS1) and a supplemental African-American cohort (here termed CHS2), which were analysed separately. ^cProgetto CUORE was analysed as 7 different studies (ie, ATENA, EMOFRI, MATISS83, MATISS87, MATISS93, MONFRI89 and MONFRI94).

eTable 2 Description of methods used to assess adiposity measures in the contributing studies

Study abbreviation ^a	Country	Year(s) of baseline survey	Measurement of height & weight	Measurement of waist & hip	Assessment of height & weight	Assessment of waist circumference	Assessment of hip circumference
ARIC	USA	1987-1989	Assessed	Assessed	participant wearing a scrub suit and no shoes	umbilical level	around the maximum buttocks
ATENA ^c	Italy	1993-1996	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
ATTICA	Greece	2001	Assessed	Assessed	light undergarments and no shoes	midway between lower rib margin and the iliac crest	around the maximum buttocks
AUSDIAB	Australia	1999-2000	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
BRHS	UK	1998-2000	Assessed	Assessed	light undergarments and no shoes	midway between lower rib margin and the iliac crest	largest circumference below the waist
BRUN	Italy	1990	Assessed	Assessed	measured after an overnight fast, subjects wearing only undergarments.	umbilical level	at greater trochanters
BWHHS	UK	1999-2001	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	largest circumference below the waist
CAPS	UK	1990-1993	Assessed	Assessed	NA	narrowest point between the costal line and the iliac crest	at greater trochanters
CHARL	USA	1987-1989	Assessed	Assessed	light clothing and no shoes	umbilical level	at greater trochanters
CHS1 ^b	USA	1989-1990	Assessed	Assessed	NA	umbilical level	maximum hip circumference
CHS2 ^b	USA	1992-1993	Assessed	Assessed	NA	umbilical level	maximum hip circumference
COPEN	Denmark	1992-1994	Assessed	Assessed	light clothing or underwear and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
DRECE	Spain	2006	Assessed	Assessed	NA	NA	NA
EMOFRI ^c	Italy	1995-1996	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
EPESENCA	USA	1992-1993	Self-reported	Assessed	NA	umbilical level	NA
EPICNOR	UK	1993-1997	Assessed	Assessed	no shoes	smallest circumference between the ribs and iliac crest	maximum circumference between the iliac crest and the crotch
FINRISK92	Finland	1992	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
FINRISK97	Finland	1997	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
FRAMOFF	USA	1998-2000	Assessed	Assessed	light clothing and no shoes	umbilical level	NA
GOH	Israel	1999-2005	Assessed	Assessed	light clothing and no shoes	one finger width above superior iliac crest	At groin level
GOTO13	Sweden	1967	Assessed	Assessed	wearing underpants	umbilical level	at the level of the anterior iliac crest
GOTO33	Sweden	1983-1984	Assessed	Assessed	after an overnight fast, indoor clothing, and 0.8 kg deducted from the recorded weight	umbilical level	at the level of the anterior iliac crest
GOTO43	Sweden	1993-1994	Assessed	Assessed	after an overnight fast, indoor clothing, and 0.8 kg deducted from the recorded weight	umbilical level	at the level of the anterior iliac crest
GOTOW	Sweden	1968-1969	Assessed	Assessed	no shoes	midway between lower rib margin and the iliac crest	widest point between hip and buttock
HBS	Finland	1986	Assessed	Assessed	without shoes and shirt	umbilical level	at the level of the anterior iliac crest

eTable 2 cont'd Description of methods used to assess adiposity measures in the contributing studies

Study abbreviation ^a	Country	Year(s) of baseline survey	Measurement of height & weight	Measurement of waist & hip	Assessment of height & weight	Assessment of waist circumference	Assessment of hip circumference
HISAYAMA	Japan	1988	Assessed	Assessed	light clothing and no shoes	umbilical level	Around the buttocks, 4cm below the anterior superior iliac spine
HOORN	Netherlands	1990-1991	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	widest level over the greater trochanters
HPFS	USA	1996	Self-reported	Self-reported	NA	umbilical level	largest circumference between the waist and thighs
IKNS	Japan	1990-1993	Assessed	Assessed	light clothing and no shoes	umbilical level	maximum circumference over the buttocks
LASA	Netherlands	1992-1993	Assessed	Assessed	light clothing	midway between lower rib margin and the iliac crest	widest level over the greater trochanters
MATISS83 ^c	Italy	1993-1996	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
MATISS87 ^c	Italy	1993-1996	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
MATISS93 ^c	Italy	1993-1995	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
MESA	USA	2001	Assessed	Assessed	light clothing and no shoes	umbilical level	NA
MOGERAUG2	Germany	1989-1990	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
MOGERAUG3	Germany	1994-1995	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
MONFRI89 ^c	Italy	1989	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
MONFRI94 ^c	Italy	1994	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
MORGEN	Netherlands	1993-1997	Assessed	Assessed	indoor clothing and no shoes	midway between lower rib margin and the iliac crest	at the level of the greater trochanters
MOSWEGOT	Sweden	1985-1995	Assessed	Assessed	light clothing and no shoes after at least 4 h of fasting	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
MRCOLD	UK	1995-1998	Assessed	Assessed	light undergarments and no shoes	midway between lower rib margin and the iliac crest (Duplicate measurements)	maximum circumference over the buttocks and below the iliac crest (Duplicate measurements)
NHANESIII	USA	1988-1993	Assessed	Assessed	paper shirt and pants and foam slippers	at level with the iliac crest at the end of a normal expiration	maximum circumference over the buttocks
NHS	USA	1986	Self-reported	Self-reported	NA	umbilical level	largest circumference around hips (including buttocks)
NSHS	Canada	1995	Assessed	Assessed	light clothing and no shoes	at the point of noticeable waist narrowing	at the level of the symphysis pubis and the greatest gluteal protuberance
OSAKA	Japan	1992-1997	Assessed	Assessed	light clothing and no shoes	umbilical level	maximum circumference over the buttocks
PREVEND	Netherlands	1997-1998	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
PRIME	France/N. Ireland	1991-1993	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	above the buttocks

eTable 2 cont'd Description of methods used to assess adiposity measures in the contributing studies

Study abbreviation ^a	Country	Year(s) of baseline survey	Measurement of height & weight	Measurement of waist & hip	Assessment of height & weight	Assessment of waist circumference	Assessment of hip circumference
RANCHO	USA	1984-1986	Assessed	Assessed	indoor clothing and no shoes	at the bending point (the natural indentation when bending sideways)	largest girth below the waist
ROTT	Netherlands	1990-1993	Assessed	Assessed	no shoes and heavy outer garments	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
SHHEC	UK	1989-1995	Assessed	Assessed	NA	NA	NA
SHS	USA	1989-1991	Assessed	Assessed	light clothing and no shoes	umbilical level	at the maximum protrusion of gluteal muscles
TARFS	Turkey	1998	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	at the level of the greater trochanters
TOYAMA	Japan	1996	Assessed	Assessed	light clothing and no shoes	midway between lower rib margin and the iliac crest	maximum circumference over the buttocks
TROMSØ	Norway	1994-1995	Assessed	Assessed	light clothing and no shoes	umbilical level	at the widest point at the hips
ULSAM	Sweden	1991-1994	Assessed	Assessed	NA	midway between lower rib margin and the iliac crest	measured over the widest part
WHIHABPS	USA	1994	Assessed	Assessed	light clothing and no shoes	at the natural waist or narrowest part of the torso	maximum circumference over the buttocks
WHITEII	UK	1991-1993	Assessed	Assessed	NA	midway between lower rib margin and the iliac crest	at the level of the greater trochanters
WHS	USA	1999-2001	Self-reported	Self-reported	NA	umbilical level	maximum circumference between the umbilicus and the thigh

^aeAppendix lists study acronyms and study references.

^bCHS included an original cohort (here termed CHS1) and a supplemental African-American cohort (here termed CHS2), which were analysed separately.

^cProgetto CUORE was analysed as 7 different studies (ie, ATENA, EMOFRI, MATISS83, MATISS87, MATISS93, MONFRI89 and MONFRI94).

Abbreviations: Assessed, anthropometric marker was assessed by a trained person; Self-reported, anthropometric marker was measured by the subject itself; NA, information not available.

eTable 3 Summary of data available and associations with adiposity measures

A

	Summary of available data on BMI, waist & hip circumference			Difference (95% CI) in row variables per 1-SD higher level of adiposity measures [‡]		
	No of studies	No of participants	Mean (SD) or %	BMI (kg/m ²)	Waist circumference (cm)	Waist-to-hip ratio
Adiposity measures						
BMI (kg/m ²)	58	221934	27 (4.56)	-	4.06 (3.95 to 4.17)	2.21 (2.05 to 2.38)
Waist circumference (cm)	58	221934	91 (12.6)	10.05 (9.85 to 10.26)	-	9.50 (9.08 to 9.91)
Waist-to-hip ratio	58	221934	0.90 (0.083)	0.03 (0.03 to 0.03)	0.05 (0.05 to 0.06)	-
BP and glucose						
Systolic BP (mmHg)	53	191170	135 (20)	4.40 (4.00 to 4.81)	4.41 (4.02 to 4.80)	3.37 (3.08 to 3.67)
Diastolic BP (mmHg)	53	191112	80 (11)	2.95 (2.60 to 3.31)	2.93 (2.59 to 3.27)	2.09 (1.83 to 2.35)
Fasting glucose (mmol/l)	34	85330	5.6 (1.8)	0.29 (0.26 to 0.32)	0.33 (0.28 to 0.37)	0.29 (0.22 to 0.36)
Lipid markers						
Total cholesterol (mmol/l)	53	179735	5.8 (1.1)	0.09 (0.06 to 0.11)	0.09 (0.07 to 0.12)	0.12 (0.10 to 0.14)
Non-HDL-cholesterol (mmol/l)	50	174024	4.40 (1.12)	0.19 (0.16 to 0.22)	0.21 (0.18 to 0.24)	0.22 (0.19 to 0.25)
HDL-cholesterol (mmol/l)	50	174095	1.40 (0.40)	-0.11 (-0.11 to -0.10)	-0.12 (-0.12 to -0.11)	-0.10 (-0.11 to -0.09)
Log _e triglyceride (mmol/l)	47	146974	0.31 (0.53)	0.16 (0.14 to 0.18)	0.18 (0.17 to 0.20)	0.18 (0.16 to 0.19)
Apo AI (g/l)	17	63156	1.53 (0.30)	-0.05 (-0.06 to -0.04)	-0.05 (-0.06 to -0.04)	-0.04 (-0.06 to -0.03)
Apo B (g/l)	16	62347	1.13 (0.30)	0.05 (0.03 to 0.06)	0.05 (0.04 to 0.07)	0.05 (0.03 to 0.07)
Log _e Lp(a) (mg/dl)	15	55520	2.45 (1.17)	0.01 (-0.02 to 0.04)	-0.01 (-0.04 to 0.01)	-0.04 (-0.07 to -0.01)
Inflammatory markers						
Fibrinogen (μmol/l)	28	97608	8.7 (2.1)	0.33 (0.27 to 0.39)	0.35 (0.28 to 0.41)	0.30 (0.24 to 0.37)
Log _e CRP (mg/l)	30	67483	0.66 (1.08)	0.33 (0.29 to 0.37)	0.36 (0.32 to 0.40)	0.31 (0.26 to 0.35)
Albumin (g/l)	19	64230	43 (3)	-0.11 (-0.25 to 0.03)	-0.10 (-0.22 to 0.03)	0.02 (-0.06 to 0.10)
Log _e leukocyte count (x10 ⁹ per l)	18	61522	1.82 (0.28)	0.03 (0.02 to 0.03)	0.03 (0.03 to 0.04)	0.04 (0.03 to 0.05)
Log _e Interleukin 6 (ng/l)	8	24290	0.57 (0.64)	0.15 (0.11 to 0.19)	0.16 (0.12 to 0.21)	0.14 (0.10 to 0.19)

[‡]Change in row variable (adiposity measure or potential mediating risk factor) per 1-SD higher levels of adiposity measure, adjusted for age and sex, pooled across studies using random effects meta-analysis.

eTable 3 cont'd Summary of data available and associations with adiposity measures

B

	No of studies	No of participants	Mean (SD) or %	Difference (95% CI) in Z-score of adiposity measures per 1-SD higher level of row variable or compared to reference category [‡]		
				BMI (kg/m ²)	Waist circumference (cm)	Waist-to-hip ratio
Age at survey (yrs)	58	221934	58 (9)	0.02 (-0.02 to 0.06)	0.11 (0.08 to 0.14)	0.15 (0.12 to 0.17)
Categorical variables						
Sex	58	221934				
Female		124189	56%	0.04 (-0.04 to 0.11)	-0.63 (-0.74 to -0.52)	-1.15 (-1.27 to -1.03)
Male		97745	44%	Ref	Ref	Ref
Ethnicity	44	145882				
Non-white		28956	20%	0.24 (0.13 to 0.35)	0.10 (0.00 to 0.20)	0.10 (0.01 to 0.18)
White		116926	80%	Ref	Ref	Ref
Smoking status	58	219092				
Current		52261	24%	-0.21 (-0.24 to -0.18)	-0.12 (-0.15 to -0.09)	0.05 (0.02 to 0.07)
Not current		166831	76%	Ref	Ref	Ref
Alcohol status	47	195186				
Current		110199	56%	-0.13 (-0.17 to -0.09)	-0.08 (-0.12 to -0.04)	-0.02 (-0.05 to 0.01)
Not current		84987	44%	Ref	Ref	Ref
History of diabetes	56	203849				
Yes		13899	7%	0.43 (0.37 to 0.49)	0.46 (0.40 to 0.52)	0.36 (0.32 to 0.41)
No		189950	93%	Ref	Ref	Ref
Level of education reached	33	125162				
Tertiary		34013	27%	-0.29 (-0.34 to -0.23)	-0.24 (-0.29 to -0.19)	-0.26 (-0.30 to -0.21)
Secondary		64186	51%	-0.17 (-0.21 to -0.13)	-0.14 (-0.18 to -0.11)	-0.13 (-0.16 to -0.10)
Primary		26963	22%	Ref	Ref	Ref

[‡]Difference in mean Z-score of adiposity measure levels per 1-SD higher levels of the row variable or compared to reference category, adjusted for age and sex, pooled across studies using random effects meta-analysis. To obtain the original scale of each adiposity measure, Z-scores have to be multiplied by the standard deviation of corresponding adiposity measure.

eTable 4 Hazard ratios for coronary heart disease and ischaemic stroke per 1-SD higher baseline BMI, waist circumference and waist-to-hip ratio levels with adjustment for baseline levels of potential mediating risk factors

Outcome / adjusted variables [†]	HR (95% CI)		
	Body-mass index	Waist circumference	Waist-to-hip ratio
Coronary heart disease			
(34 studies, 114083 participants & 4800 cases)			
Adjusted for age, sex and smoking	1.28 (1.21 to 1.36)	1.30 (1.23 to 1.37)	1.30 (1.22 to 1.38)
plus intermediate risk factors	1.10 (1.05 to 1.16)	1.11 (1.06 to 1.17)	1.14 (1.10 to 1.18)
plus log _e triglyceride	1.10 (1.05 to 1.15)	1.11 (1.06 to 1.16)	1.15 (1.11 to 1.19)
(21 studies, 50492 participants & 2854 cases)			
Adjusted for age, sex and smoking	1.26 (1.17 to 1.35)	1.28 (1.19 to 1.38)	1.28 (1.19 to 1.37)
plus possible intermediate risk factors	1.10 (1.02 to 1.18)	1.11 (1.03 to 1.20)	1.12 (1.07 to 1.17)
plus log _e C-reactive protein	1.04 (0.97 to 1.12)	1.05 (0.98 to 1.13)	1.08 (1.04 to 1.13)
(21 studies, 82557 participants & 3568 cases)			
Adjusted for age, sex and smoking	1.25 (1.16 to 1.34)	1.26 (1.17 to 1.35)	1.27 (1.18 to 1.37)
plus intermediate risk factors	1.08 (1.01 to 1.14)	1.08 (1.02 to 1.15)	1.13 (1.09 to 1.18)
plus fibrinogen	1.06 (1.00 to 1.12)	1.06 (1.00 to 1.12)	1.13 (1.09 to 1.18)
Ischaemic stroke			
(20 studies, 81017 participants & 2395 cases)			
Adjusted for age, sex and smoking	1.19 (1.11 to 1.28)	1.25 (1.18 to 1.33)	1.25 (1.18 to 1.33)
plus intermediate risk factors	1.06 (0.99 to 1.13)	1.11 (1.05 to 1.17)	1.15 (1.09 to 1.21)
plus log _e triglyceride	1.06 (0.99 to 1.13)	1.11 (1.05 to 1.18)	1.15 (1.09 to 1.21)
(12 studies, 30758 participants & 1656 cases)			
Adjusted for age, sex and smoking	1.16 (1.08 to 1.25)	1.21 (1.13 to 1.29)	1.22 (1.13 to 1.31)
plus intermediate risk factors	1.07 (0.98 to 1.16)	1.11 (1.03 to 1.20)	1.15 (1.06 to 1.25)
plus log _e C-reactive protein	1.02 (0.95 to 1.10)	1.11 (1.03 to 1.20)	1.13 (1.04 to 1.23)
(15 studies, 59328 participants & 1856 cases)			
Adjusted for age, sex and smoking	1.21 (1.12 to 1.31)	1.26 (1.18 to 1.34)	1.28 (1.17 to 1.39)
plus intermediate risk factors	1.08 (1.00 to 1.16)	1.12 (1.05 to 1.18)	1.17 (1.08 to 1.25)
plus fibrinogen	1.06 (0.99 to 1.13)	1.11 (1.05 to 1.17)	1.16 (1.08 to 1.24)

[†]Intermediate risk factors were systolic blood pressure, history of diabetes, and total and HDL cholesterol.


Hazard ratios (HRs) are presented per 4.56 kg/m² higher BMI, 12.6 cm higher waist circumference and 0.083 higher waist-to-hip ratio (ie, 1-SD higher baseline values). Analyses are restricted to participants with BMI values of 20 kg/m² or higher and complete information on age, sex, smoking status, and intermediate risk factors plus triglyceride, CRP or fibrinogen in turn.

eTable 5 Reclassification of 10-year predicted risk of cardiovascular disease after addition of BMI or waist-to-hip ratio or total and HDL-cholesterol measures to a non-lipid-based model

	Body-mass index	Waist-to-hip ratio	Total cholesterol & HDL-C
Reclassification (20 studies, 4777 cases, 43944 non-cases)			
Participants who developed CVD at 10 years			
Appropriately reclassified	159 (3.33%)	211 (4.42%)	509 (10.66%)
Inappropriately reclassified	137 (2.87%)	189 (3.96%)	381 (7.98%)
No change	4481 (93.80%)	4377 (91.63%)	3887 (81.37%)
Participants who were event free at 10 years			
Appropriately reclassified	1033 (2.35%)	1572 (3.58%)	3095 (7.04)
Inappropriately reclassified	1161 (2.64%)	1544 (3.51%)	3027 (6.89%)
No change	41750 (95.01%)	40828 (92.91%)	37822 (86.07%)
NRI (95% CI)	0.17% (-0.57%, 0.91%)	0.52% (-0.33%, 1.38%)	2.83% (1.56%, 4.11%)
p-value	0.652	0.231	<0.0001
IDI (95% CI)	0.0005 (0.0001, 0.0010)	0.0019 (0.0012, 0.0026)	0.0059 (0.0046, 0.0072)
p-value	0.022	<0.001	<0.0001


Non-lipid-based variables were age, smoking status, systolic blood pressure and history of diabetes. Model was stratified by sex. Analyses are restricted to cohorts and participants with BMI of 20 kg/m² or higher. Cohort studies recording both fatal and non-fatal cardiovascular outcomes and more than 10 years of follow-up contributed to reclassification analyses. NRI, Net Reclassification Improvement; IDI, Integrated Discrimination Improvement.

eFigure 1 Flow diagram showing steps involved in study selection for the current analysis




To be eligible for inclusion in the Emerging Risk Factors Collaboration (ERFC), prospective studies (reported variously as observational cohort studies, trials, or analyses of nested case-control or case-cohort subsets) had: (1) data available from baseline measurements of at least one of the relevant markers assessed; (2) at least 1 year of follow-up; (3) participants not selected on the basis of having previous cardiovascular diseases; and (4) information on cause-specific mortality and/or major cardiovascular morbidity collected during follow-up. Studies were included if they were known to have recorded at least 20 000 person years at risk. Most eligible studies were identified in previously published meta-analyses, with additional studies identified through updated computer-assisted literature searches of databases, scanning of reference lists, hand-searching of relevant journals and correspondence with authors of relevant reports. Further details of the ERFC (including search strategies, contributing studies, data provision and management, and other characteristics) have been reported previously (*Eur J Epidemiol.* 2007;22:839-869).

eFigure 2 Mean adiposity measure levels in each study (part a), according to quantiles of adiposity measures (part b) and within 5-year age bands (part c)




For cross-sectional associations between adiposity measures (part b), see also footnote to eFigures 3-4. The values presented above each figure in part b correspond to the age- and sex- adjusted partial correlation coefficient (95% CI) between adiposity measures in males and females combined. eAppendix lists study acronyms.

Figure 3 Cross-sectional associations of adiposity measures with lipid markers




Mean lipid levels were adjusted to age 50 years. The values presented above each figure correspond to the age- and sex-adjusted partial correlation coefficient (95% CI) between lipid markers and adiposity measures in males and females combined. Lowest waist/hip ratio category in males was removed because it included only a few individuals. Error bars represent the 95% CIs.

Figure 4 Cross-sectional associations of adiposity measures with systolic blood pressure, fasting glucose and some inflammatory markers




Mean risk factor levels were adjusted to age 50 years. The values presented above each figure correspond to the age- and sex- adjusted partial correlation coefficient (95% CI) between risk markers and adiposity measures in males and females combined. Lowest waist/hip ratio category in males was removed because it included only a few individuals. Error bars represent the 95% CIs.

Figure 5 Mean risk factors levels across thirds of waist circumference and waist-to-hip ratio by baseline BMI levels




eFigure 6 Mean waist circumference and waist-to-hip ratio levels by diabetes status at baseline, according to deciles of BMI levels



Mean waist circumference and waist-to-hip ratio levels were adjusted to age 50 years. Age, sex and BMI adjusted differences between people with and without history of diabetes were 1.52cm (95% CI: 1.27cm-1.77cm) with waist circumference and 0.018 (95% CI: 0.015-0.021) with waist-to-hip ratio. Error bars represent the 95% CIs.


Figure 7 Regression dilution ratios for adiposity measure levels plotted against time since baseline measurement by study



Analyses were adjusted for age at baseline and sex. Re-surveys after 20 years since baseline were excluded from figure. CI indicates confidence interval. The RDRs for waist/hip ratio are lower in comparison to the separate RDRs for waist and hip, largely due to a relative decrease in the between-person variance for the ratio measure as a result of highly correlated and similarly distributed waist and hip measures (ie, for two similarly distributed measures, the between-person variance of the ratio tends to zero as their correlation approaches one). The reduction in the between-person variability leads to a relatively larger within-person variance and subsequently reduced RDRs.

RDRs were 0.75 (0.72, 0.79) for HDL-C, 0.63 (0.59, 0.67) for non-HDL-C, 0.65 (0.61, 0.68) for \log_e triglyceride, and 0.57 (0.52, 0.61) for systolic blood pressure.

Figure 8 Hazard ratios for coronary heart disease by clinically defined categories of baseline BMI and waist circumference levels




*Reference group

[†]Sex and smoking adjusted incidence rates of CHD per 1000 person-years. Analyses excluded nested case-control studies and were based on 215,856 participants (involving 7397 cases).


Analysis was based on 214,169 participants (involving 8097 cases) from 52 studies. Hazard ratios (HRs) were adjusted for age and smoking status at baseline, and stratified, where appropriate, by sex. Adjusted study-specific log HRs were combined by multivariate random effects meta-analysis. High waist circumference (WC) was defined as waist circumference >102 cm in men and waist circumference >88 cm in women.

Figure 9 Hazard ratios for coronary heart disease and ischaemic stroke across quintiles of baseline BMI, waist circumference and waist-to-hip ratio levels, among men and women




Analyses were restricted to studies with data on both males and females. Analyses for coronary heart disease were based on 67001 men (involving 3818 cases) and 78197 women (involving 2719 cases) from 19 studies. Analyses for ischaemic stroke were based on 32806 men (involving 883 cases) and 42295 women (involving 1034 cases) from 16 studies. Regression analyses were adjusted for age and smoking status. Adjusted study-specific log hazard ratios were combined by multivariate random effects meta-analysis. The y-axes are shown on a log scale.

eFigure 10 Hazard ratios for coronary heart disease across thirds of waist circumference and waist-to-hip ratio by baseline levels of triglyceride




Analysis was based on 141,203 participants (involving 5684 cases) from 41 studies. Regression analyses were adjusted for age at baseline and smoking status, and stratified, where appropriate, by sex. Adjusted study-specific log hazard ratios were combined by multivariate random effects meta-analysis. The y-axes are shown on a log scale. Referent groups are the lowest third of waist circumference or waist-to-hip ratio in the lower level of triglyceride.

eFigure 11 Hazard ratios for coronary heart disease per 1-SD higher baseline BMI, waist circumference and waist-to-hip ratio levels, according to several individual and study level characteristics



Study-specific hazard ratios (HRs) were adjusted for age and smoking, and stratified, where appropriate, by sex. Analyses were restricted to participant with BMI values of 20 kg/m² or higher. CI indicates confidence interval. NA, not applicable


eFigure 12 Study-specific hazard ratios for coronary heart disease per 1-SD higher baseline levels of adiposity measures, adjusted for age, sex, and smoking status in the BMI range ≥ 20 kg/m²



Analyses were restricted to participants with BMI values of 20 kg/m² or higher and complete information on age, sex, smoking status, history of diabetes, systolic blood pressure and total and HDL cholesterol.

In the BMI analysis, after excluding the 6 most discrepant studies (CHARL, MATISS87, NHANESIII, MORGEN, TOYOMA, WHITEII) the hazard ratio was 1.26 (95% CI 1.20, 1.33) and the I² was reduced to 45% (95% CI 17%-64%). In the WC analysis, after excluding the 6 most discrepant studies (CHARL, NHANESIII, ROTT, ATENA, GOTO43, MORGEN) the hazard ratio was 1.31 (95% CI 1.25, 1.38) and the I² was reduced to 40% (95% CI 9%-61%). In the waist/hip ratio analysis, after excluding the 6 most discrepant studies (MATISS83, MATISS87, ROTT, GOTO43, MATISS93, MORGEN) the hazard ratio was 1.30 (95% CI 1.22, 1.37) and the I² was reduced to 61% (95% CI 43%-73%).


eFigure 13 Funnel plots assessing potential bias due to small studies in the meta-analysis of adiposity measure and coronary heart disease risk



Analyses were restricted to participants with BMI values of 20 kg/m² or higher and complete information on age, sex, smoking status, history of diabetes, systolic blood pressure, and total and HDL cholesterol. Dotted lines represent pseudo 95% CI.

There was no evidence of bias from small-study effects for BMI ($p=0.123$), waist circumference ($p=0.211$) and waist-to-hip ratio ($p=0.414$) using Egger's test of small-study effects.


eFigure 14 Changes in C-index for cardiovascular disease risk prediction on omission of individual risk factors from a full model containing the Framingham risk score covariates plus BMI, waist circumference or waist-to-hip ratio in participants without diabetes at baseline



*The Framingham covariates include age, smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol. Model was stratified by sex.

Analyses involved 134,287 participants (39 studies) with 6715 cardiovascular events. Analyses are restricted to participants with BMI values of 20 kg/m² or higher.

eFigure 15 Changes in C-index for cardiovascular disease risk prediction upon addition of BMI, waist circumference or waist-to-hip ratio on top of Framingham risk score covariates, according to different subgroups



Models contain all Framingham covariates (age, systolic blood pressure, smoking status, history of diabetes and total and HDL-cholesterol) with and without inclusion of BMI, waist circumference or waist-to-hip ratio. Predictive ability added by BMI, waist circumference or waist-to-hip ratio is given, with a p-value testing the null hypothesis of no difference in effect between levels of each subgroup. Error bars indicate 95% confidence limits. In each case only studies with information on both subgroup levels are used. Not all studies used had full information across all subgroups levels, so comparisons across subgroups (eg, men vs smokers) are not reliable due to inclusion of between study differences.

eAppendix List of study acronyms and study references

ARIC, Atherosclerosis Risk in Communities Study
ATTICA, ATTICA Study
AUSDIAB, Australian Diabetes, Obesity and Lifestyle Study
BRHS, British Regional Heart Study
BRUN, Bruneck Study
BWHHS, British Women's Heart and Health Study
CAPS, Caerphilly Prospective Study
CHARL, Charleston Heart Study
CHS, Cardiovascular Health Study
COPEN, Copenhagen City Heart Study
CUORE, Progetto CUORE
DRECE, Diet and Risk of Cardiovascular Disease in Spain
EPESENCA, The Established Populations for the Epidemiologic Study of the Elderly Studies, North Carolina
EPICNOR, EPIC Norfolk Study
FINRISK92, Finrisk Cohort 1992
FINRISK97, Finrisk Cohort 1997
FRAMOFF, Framingham Offspring Cohort
GOH, The Glucose Intolerance, Obesity and Hypertension Study
GOTO13, Göteborg 1913 Study
GOTO33, Göteborg 1933 Study
GOTO43, Göteborg 1943 Study
GOTOW, Population Study of Women in Gothenburg, Sweden
HBS, Helsinki Businessmen Study
HISAYAMA, Hisayama Study
HOORN, Hoorn Study
HPFS, Health Professionals Follow-up Study
IKNS, Ikawa, Kyowa, and Noichi Study
LASA, Longitudinal Aging Study Amsterdam
MESA, Multi-Ethnic Study of Atherosclerosis
MOGERAUG2, MONICA/KORA Augsburg Survey S2
MOGERAUG3, MONICA/KORA Augsburg Survey S3
MORGEN, Monitoring Project on Chronic Disease Risk Factors
MOSWEGOT, MONICA Göteborg Study
MRCOLD, MRC Study of Older People
NHANESIII, Third National Health and Nutrition Examination Survey
NHS, Nurses' Health Study
NSHS, Nova Scotia Health Survey
OSAKA, Osaka Study
PREVEND, Prevention of Renal and Vascular End Stage Disease Study
PRIME, Prospective Epidemiological Study of Myocardial Infarction
RANCHO, Rancho Bernardo Study
ROTT, The Rotterdam Study
SHHEC, Scottish Heart Health Extended Cohort
SHS, Strong Heart Study
TARFS, Turkish Adult Risk Factor Study
TOYAMA, Toyama
TROMSØ, Tromsø Study
ULSAM, Uppsala Longitudinal Study of Adult Men
WHIHBAPS, Women's Health Initiative (Hormones and Biomarkers Predicting Stroke in Women)
WHITE2, Whitehall II Study
WHS, Women's Health Study

Reference list of participating studies (48 references represent the 58 studies that provided data relevant to these analyses)

- (1) Folsom AR, Stevens J, Schreiner PJ, McGovern PG. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Atherosclerosis Risk in Communities Study Investigators. *Am J Epidemiol*. 1998;148:1187-1194.
- (2) Panagiotakos DB, Chrysohoou C, Pitsavos C et al. Hierarchical analysis of anthropometric indices in the prediction of 5-year incidence of hypertension in apparently healthy adults: the ATTICA study. *Atherosclerosis*. 2009;206:314-320.
- (3) Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE. Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. *Int J Obes Relat Metab Disord*. 2004;28:402-409.
- (4) Lawlor DA, Ebrahim S, Whincup P et al. Sex differences in body fat distribution and carotid intima media thickness: cross sectional survey using data from the British regional heart study. *J Epidemiol Community Health*. 2004;58:700-704.
- (5) Bonora E, Kiechl S, Willeit J et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. *Int J Obes Relat Metab Disord*. 2003;27:1283-1289.
- (6) Lawlor DA, Davey Smith G, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. *Cancer Causes Control*. 2004;15:267-275.
- (7) Yarnell JW, Patterson CC, Thomas HF, Sweetnam PM. Central obesity: predictive value of skinfold measurements for subsequent ischaemic heart disease at 14 years follow-up in the Caerphilly Study. *Int J Obes Relat Metab Disord*. 2001;25:1546-1549.
- (8) Stevens J, Keil JE, Rust PF et al. Body mass index and body girths as predictors of mortality in black and white men. *Am J Epidemiol*. 1992;135:1137-1146.
- (9) Mozaffarian D, Kamineni A, Carnethon M, Djousse L, Mukamal KJ, Siscovick D. Lifestyle risk factors and new-onset diabetes mellitus in older adults: the cardiovascular health study. *Arch Intern Med*. 2009;169:798-807.
- (10) Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. *Arterioscler Thromb Vasc Biol*. 2007;27:661-670.
- (11) Giampaoli S, Palmieri L, Panico S et al. Favorable cardiovascular risk profile (low risk) and 10-year stroke incidence in women and men: findings from 12 Italian population samples. *Am J Epidemiol*. 2006;163:893-902.
- (12) Ballesteros-Pomar MD, Rubio-Herrera MA, Gutierrez-Fuentes JA et al. Dietary habits and cardiovascular risk in the Spanish population: the DRECE study (I). Diet and Cardiovascular Events Risk in Spain. *Ann Nutr Metab*. 2000;44:108-114.
- (13) Blazer DG, Hybels CF, Fillenbaum GG. Metabolic syndrome predicts mobility decline in a community-based sample of older adults. *J Am Geriatr Soc*. 2006;54:502-506.
- (14) Lahti-Koski M, Pietinen P, Heliovaara M, Vartiainen E. Associations of body mass index and obesity with physical activity, food choices, alcohol intake, and smoking in the 1982-1997 FINRISK Studies. *Am J Clin Nutr*. 2002;75:809-817.
- (15) McKeown NM, Meigs JB, Liu S, Wilson PW, Jacques PF. Whole-grain intake is favorably associated with metabolic risk factors for type 2 diabetes and cardiovascular disease in the Framingham Offspring Study. *Am J Clin Nutr*. 2002;76:390-398.
- (16) Modan M, Halkin H, Fuchs Z et al. Hyperinsulinemia--a link between glucose intolerance, obesity, hypertension, dyslipoproteinemia, elevated serum uric acid and internal cation imbalance. *Diabete Metab*. 1987;13:375-380.
- (17) Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. *Br Med J (Clin Res Ed)*. 1984;288:1401-1404.
- (18) Rosengren A, Eriksson H, Larsson B et al. Secular changes in cardiovascular risk factors over 30 years in Swedish men aged 50: the study of men born in 1913, 1923, 1933 and 1943. *J Intern Med*. 2000;247:111-118.
- (19) Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. *Br Med J (Clin Res Ed)*. 1984;289:1257-1261.
- (20) Strandberg TE, Salomaa VV, Vanhanen HT, Naukkarinen VA, Sarna SJ, Miettinen TA. Mortality in participants and non-participants of a multifactorial prevention study of cardiovascular diseases: a 28 year follow up of the Helsinki Businessmen Study. *Br Heart J*. 1995;74:449-454.

- (21) Nakashima Y, Kiyohara Y, Doi Y, Kubo M, Iida M, Sueishi K. Risk factors for coronary atherosclerosis in a general Japanese population: the Hisayama study. *Pathol Res Pract*. 2009;205:700-708.
- (22) Wedick NM, Snijder MB, Dekker JM et al. Prospective investigation of metabolic characteristics in relation to weight gain in older adults: the Hoorn Study. *Obesity (Silver Spring)*. 2009;17:1609-1614.
- (23) Iso H, Naito Y, Sato S et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. *Am J Epidemiol*. 2001;153:490-499.
- (24) Visser M, Launer LJ, Deurenberg P, Deeg DJ. Total and sports activity in older men and women: relation with body fat distribution. *Am J Epidemiol*. 1997;145:752-761.
- (25) Bahrami H, Bluemke DA, Kronmal R et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol*. 2008;51:1775-1783.
- (26) Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. *Am J Clin Nutr*. 2006;84:483-489.
- (27) van D, I, Kromhout D, Geleijnse JM, Boer JM, Verschuren WM. Body mass index and waist circumference predict both 10-year nonfatal and fatal cardiovascular disease risk: study conducted in 20 000 Dutch men and women aged 20-65 years. *Eur J Cardiovasc Prev Rehabil*. 2009.
- (28) Wilhelmsen L, Johansson S, Rosengren A, Wallin I, Dotevall A, Lappas G. Risk factors for cardiovascular disease during the period 1985-1995 in Goteborg, Sweden. The GOT-MONICA Project. *J Intern Med*. 1997;242:199-211.
- (29) Price GM, Uauy R, Breeze E, Bulpitt CJ, Fletcher AE. Weight, shape, and mortality risk in older persons: elevated waist-hip ratio, not high body mass index, is associated with a greater risk of death. *Am J Clin Nutr*. 2006;84:449-460.
- (30) Reis JP, Macera CA, Araneta MR, Lindsay SP, Marshall SJ, Wingard DL. Comparison of overall obesity and body fat distribution in predicting risk of mortality. *Obesity (Silver Spring)*. 2009;17:1232-1239.
- (31) Davidson KW, Schwartz JE, Kirkland SA et al. Relation of inflammation to depression and incident coronary heart disease (from the Canadian Nova Scotia Health Survey [NSHS95] Prospective Population Study). *Am J Cardiol*. 2009;103:755-761.
- (32) Kitamura A, Sato S, Kiyama M et al. Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka study. *J Am Coll Cardiol*. 2008;52:71-79.
- (33) Pinto-Sietsma SJ, Navis G, Janssen WM, de ZD, Gans RO, de Jong PE. A central body fat distribution is related to renal function impairment, even in lean subjects. *Am J Kidney Dis*. 2003;41:733-741.
- (34) Gruson E, Montaye M, Kee F et al. Anthropometric assessment of abdominal obesity and coronary heart disease risk in men : the PRIME study. *Heart*. 2009.
- (35) Kim DJ, Bergstrom J, Barrett-Connor E, Laughlin GA. Visceral adiposity and subclinical coronary artery disease in elderly adults: Rancho Bernardo Study. *Obesity (Silver Spring)*. 2008;16:853-858.
- (36) Visscher TL, Seidell JC, Molarius A, van der KD, Hofman A, Witteman JC. A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study. *Int J Obes Relat Metab Disord*. 2001;25:1730-1735.
- (37) Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). *Heart*. 2007;93:172-176.
- (38) Welty TK, Lee ET, Yeh J et al. Cardiovascular disease risk factors among American Indians. The Strong Heart Study. *Am J Epidemiol*. 1995;142:269-287.
- (39) Onat A, Avci GS, Barlan MM, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. *Int J Obes Relat Metab Disord*. 2004;28:1018-1025.
- (40) Sakurai M, Miura K, Takamura T et al. Gender differences in the association between anthropometric indices of obesity and blood pressure in Japanese. *Hypertens Res*. 2006;29:75-80.
- (41) Borch KH, Braekkan SK, Mathiesen EB et al. Anthropometric Measures of Obesity and Risk of Venous Thromboembolism. The Tromso Study. *Arterioscler Thromb Vasc Biol*. 2009.
- (42) Riserus U, Ingelsson E. Alcohol intake, insulin resistance, and abdominal obesity in elderly men. *Obesity (Silver Spring)*. 2007;15:1766-1773.

- (43) Hamer M, Steptoe A. Prospective study of physical fitness, adiposity, and inflammatory markers in healthy middle-aged men and women. *Am J Clin Nutr.* 2009;89:85-89.
- (44) Gelber RP, Gaziano JM, Orav EJ, Manson JE, Buring JE, Kurth T. Measures of obesity and cardiovascular risk among men and women. *J Am Coll Cardiol.* 2008;52:605-615.
- (45) Canoy D, Boekholdt SM, Wareham N et al. Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. *Circulation.* 2007;116:2933-2943.
- (46) Rimm EB, Stampfer MJ, Giovannucci E et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. *Am J Epidemiol.* 1995;141:1117-1127.
- (47) Rexrode KM, Carey VJ, Hennekens CH et al. Abdominal adiposity and coronary heart disease in women. *JAMA.* 1998;280:1843-1848.
- (48) Kaplan RC, McGinn AP, Baird AE et al. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study. *J Stroke Cerebrovasc Dis.* 2008;17:344-355.